These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 21605410)

  • 1. Characterization of hepatitis C Virus genotype 3a hypervariable region 1 in patients achieved rapid virological response to alpha interferon and ribavirin combination therapy.
    Akram M; Idrees M; Hussain A; Afzal S; Ilyas M; Zafar S; Aftab M; Badar S; Khubaib B
    Virol J; 2011 May; 8():253. PubMed ID: 21605410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy.
    Vuillermoz I; Khattab E; Sablon E; Ottevaere I; Durantel D; Vieux C; Trepo C; Zoulim F
    J Med Virol; 2004 Sep; 74(1):41-53. PubMed ID: 15258967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection.
    Murphy MD; Rosen HR; Marousek GI; Chou S
    Dig Dis Sci; 2002 Jun; 47(6):1195-205. PubMed ID: 12064791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus quasispecies in chronically infected children subjected to interferon-ribavirin therapy.
    Figlerowicz M; Jackowiak P; Formanowicz P; Kędziora P; Alejska M; Malinowska N; Błażewicz J; Figlerowicz M
    Arch Virol; 2010 Dec; 155(12):1977-87. PubMed ID: 20842394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen.
    Lunel F; Veillon P; Fouchard-Hubert I; Loustaud-Ratti V; Abergel A; Silvain C; Rifflet H; Blanchi A; Causse X; Bacq Y; Payan C;
    J Hepatol; 2003 Nov; 39(5):826-33. PubMed ID: 14568267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary structure of the amino-terminal region of HCV NS3 and virological response to pegylated interferon plus ribavirin therapy for chronic hepatitis C.
    Sanjo M; Saito T; Ishii R; Nishise Y; Haga H; Okumoto K; Ito J; Watanabe H; Saito K; Togashi H; Fukuda K; Imai Y; El-Shamy A; Deng L; Shoji I; Hotta H; Kawata S
    J Med Virol; 2010 Aug; 82(8):1364-70. PubMed ID: 20572079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2009 Mar; 81(3):452-8. PubMed ID: 19152407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C.
    Pawlotsky JM; Pellerin M; Bouvier M; Roudot-Thoraval F; Germanidis G; Bastie A; Darthuy F; Rémiré J; Soussy CJ; Dhumeaux D
    J Med Virol; 1998 Apr; 54(4):256-64. PubMed ID: 9557291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in the E2-PePHD region of hepatitis C virus genotype-3a and correlation with response to interferon and ribavirin combination therapy in Pakistani patients.
    Afzal S; Idrees M; Akram M; Awan Z; Khubaib B; Aftab M; Fatima Z; Badar S; Hussain A
    Virol J; 2010 Dec; 7():377. PubMed ID: 21194456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection.
    Chambers TJ; Fan X; Droll DA; Hembrador E; Slater T; Nickells MW; Dustin LB; Dibisceglie AM
    J Virol; 2005 Mar; 79(5):3071-83. PubMed ID: 15709027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deep sequencing of hepatitis C virus hypervariable region 1 reveals no correlation between genetic heterogeneity and antiviral treatment outcome.
    Cortés KC; Zagordi O; Perlejewski K; Laskus T; Maroszek K; Bukowska-Ośko I; Pawełczyk A; Płoski R; Berak H; Horban A; Radkowski M
    BMC Infect Dis; 2014 Jul; 14():389. PubMed ID: 25016390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Matsuda M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    Intervirology; 2005; 48(6):372-80. PubMed ID: 16024941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amino acid sequence analysis in patients with chronic HCV genotype 1b infection during pegylated interferon-α2a and ribavirin therapy.
    Fu JJ; Kong WJ; Jiang D; Pan XC; Wei L
    Antivir Ther; 2014; 19(7):661-8. PubMed ID: 24584067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.
    Crespo M; Esteban JI; Ribera E; Falco V; Sauleda S; Buti M; Esteban R; Guardia J; Ocaña I; Pahissa A
    AIDS; 2007 Feb; 21(4):477-81. PubMed ID: 17301566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Chayama K; Nakamura Y; Kumada H
    Hepatology; 2010 Aug; 52(2):421-9. PubMed ID: 20648473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations within the hepatitis C virus genotype 1b E2-PePHD domain do not correlate with treatment outcome.
    Gaudy C; Lambelé M; Moreau A; Veillon P; Lunel F; Goudeau A
    J Clin Microbiol; 2005 Feb; 43(2):750-4. PubMed ID: 15695675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peginterferon alpha-2b plus ribavirin for chronic hepatitis C virus mixed genotype infection.
    Lin CC; Wu CH; Chen HL; Lin IT; Wang SY; Wang TE; Wang HY; Shih SC; Bair MJ
    Ann Hepatol; 2014; 13(4):350-5. PubMed ID: 24927605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study.
    Rumi MG; Aghemo A; D'Ambrosio R; Ronchi G; Del Ninno E; Gallus S; Colombo M
    Antivir Ther; 2007; 12(7):1033-40. PubMed ID: 18018761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.